Moxifloxacină Rompharm (Moxifloxacin Hydrochloride)

Moxifloxacin is indicated for bacterial ocular infections, targeting common pathogens that affect the eye surface and cornea.

• Bacterial conjunctivitis: reduces bacterial load and accelerates symptom resolution in acute conjunctival infection.
• Bacterial keratitis: eradicates causative organisms and promotes corneal healing in infectious keratitis.
• Post‑operative ocular infection: prevents or treats bacterial contamination following eye surgery.
• Corneal ulcer: facilitates healing of bacterial corneal ulcers and limits scarring.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for supercoiling and separation of replicated DNA. By binding to the quinolone‑resistance‑determining region of these enzymes, it prevents DNA replication and transcription, leading to bacterial cell death. The high affinity for both Gram‑positive and Gram‑negative ocular pathogens underlies its broad‑spectrum activity in eye infections.

Moxifloxacin eye drops may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

• Eye irritation: transient burning or stinging sensation after instillation.
• Redness: mild conjunctival hyperemia.
• Tearing: increased lacrimation.
• Foreign body sensation: feeling of grit in the eye.
• Blurred vision: temporary visual disturbance.
• Photophobia: heightened sensitivity to light.

Serious or Rare Side Effects

• Corneal ulceration: worsening of corneal lesions.
• Allergic reaction: eyelid edema, rash, or anaphylaxis.
• Stevens‑Johnson syndrome: severe mucocutaneous eruption.
• Tendon rupture: rare systemic effect, especially with systemic exposure.
• Severe ocular inflammation: uveitis or keratitis exacerbation.

Before prescribing Moxifloxacin ophthalmic solution, clinicians should consider several safety precautions to minimize risks.

• Allergy assessment: avoid use in patients with known hypersensitivity to fluoroquinolones or any component of the formulation.
• Contact lens use: discontinue contact lenses during treatment to prevent drug absorption and irritation.
• Corneal disease: use with caution in patients with pre‑existing corneal epithelial defects or severe dry eye.
• Systemic exposure: monitor for systemic fluoroquinolone adverse effects in patients receiving concurrent oral or intravenous therapy.
• Concomitant steroids: avoid or limit topical corticosteroids as they may mask infection progression.
• Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk, as safety data are limited.
• Store at ambient temperature: keep the product in its original container, protect from light and moisture, and store below 25 °C.

Moxifloxacin can interact with other ophthalmic or systemic agents, influencing its efficacy or safety.

Major Interactions (Avoid)

• Systemic fluoroquinolones: concurrent use may increase risk of tendon rupture and central nervous system effects.
• Cation‑containing eye drops (e.g., aluminum, calcium, magnesium): may chelate the drug and markedly reduce ocular absorption.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may suppress inflammatory signs and conceal worsening infection.
• Non‑steroidal anti‑inflammatory eye drops: could increase irritation or affect healing.
• Anticholinergic agents: may exacerbate dry eye, enhancing discomfort with the ophthalmic solution.